LIVIVO - Search results -

Search results

Result 1 - 10 of total 141

Search options

Article ; Online: [No title information]

Ng, T S Brandon / Leblanc, Kori / Yeung, Darwin F / Tsang, Teresa S M

Canadian family physician Medecin de famille canadien

2021 Volume 67, Issue 3, Page(s) e69–e78

Title translation	Médicaments utilisés durant la COVID-19: Examen des données probantes récentes.
MeSH term(s)	COVID-19/epidemiology ; Drug Therapy ; Humans ; Pharmaceutical Preparations ; SARS-CoV-2 ; COVID-19 Drug Treatment
Chemical Substances	Pharmaceutical Preparations
Language	French
Publishing date	2021-03-16
Publishing country	Canada
Document type	Journal Article ; Review
ZDB-ID	603565-6
ISSN	1715-5258 ; 0008-350X
ISSN (online)	1715-5258
ISSN	0008-350X
DOI	10.46747/cfp.6703e69
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2236: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MG 5: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Medication use during COVID-19: Review of recent evidence.

Ng, T S Brandon / Leblanc, Kori / Yeung, Darwin F / Tsang, Teresa S M

Canadian family physician Medecin de famille canadien

2021 Volume 67, Issue 3, Page(s) 171–179

Abstract: Objective: To keep health care providers, in response to the ongoing coronavirus disease 2019 (COVID-19) pandemic, informed about the medications that have been proposed to treat the disease and the evidence supporting their use.: Quality of evidence!# ...

Abstract	Objective: To keep health care providers, in response to the ongoing coronavirus disease 2019 (COVID-19) pandemic, informed about the medications that have been proposed to treat the disease and the evidence supporting their use. Quality of evidence: A narrative review of medications most widely used to treat COVID-19 was conducted, outlining the best available evidence for each pharmacologic treatment to date. Searches were performed in PubMed, EMBASE, and MEDLINE using key words Main message: While current management of patients with COVID-19 largely involves supportive care, without a widely available vaccine, practitioners have also resorted to repurposing medications used for other indications. This has caused considerable controversy, as many of these treatments have limited clinical evidence supporting their use and therefore pose implications for patient safety, drug access, and public health. For instance, medications such as hydroxychloroquine and chloroquine, lopinavir-ritonavir, nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers gained widespread media attention owing to hype, misinformation, or misinterpretation of research evidence. Conclusion: Given the severity of the pandemic and the potential broad effects of implementing safe and effective treatment, this article provides a narrative review of the current evidence behind the most widely used medications to treat COVID-19 in order to enable health care practitioners to make informed decisions in the care of patients with this life-threatening disease.
MeSH term(s)	Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Antiviral Agents/therapeutic use ; Chloroquine/therapeutic use ; Drug Therapy, Combination ; Evidence-Based Medicine ; Humans ; Hydroxychloroquine/therapeutic use ; Immunoglobulins/therapeutic use ; COVID-19 Drug Treatment
Chemical Substances	Angiotensin-Converting Enzyme Inhibitors ; Antiviral Agents ; Immunoglobulins ; Hydroxychloroquine (4QWG6N8QKH) ; Chloroquine (886U3H6UFF)
Language	English
Publishing date	2021-03-16
Publishing country	Canada
Document type	Journal Article ; Review
ZDB-ID	603565-6
ISSN	1715-5258 ; 0008-350X
ISSN (online)	1715-5258
ISSN	0008-350X
DOI	10.46747/cfp.6703171
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2236: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MG 5: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: KCC2 is required for the survival of mature neurons but not for their development.

Kontou, Georgina / Josephine Ng, Shu Fun / Cardarelli, Ross A / Howden, Jack H / Choi, Catherine / Ren, Qiu / Rodriguez Santos, Miguel A / Bope, Christopher E / Dengler, Jake S / Kelley, Matt R / Davies, Paul A / Kittler, Josef T / Brandon, Nicholas J / Moss, Stephen J / Smalley, Joshua L

The Journal of biological chemistry

2021 Volume 296, Page(s) 100364

Abstract: ... The ... ...

Abstract	The K
MeSH term(s)	Animals ; Apoptosis ; Chlorides/metabolism ; Female ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; Neurogenesis/drug effects ; Neurons/metabolism ; Neurons/physiology ; Potassium/metabolism ; Primary Cell Culture ; Receptors, GABA/metabolism ; Seizures ; Symporters/metabolism ; Symporters/physiology ; gamma-Aminobutyric Acid/metabolism ; K Cl- Cotransporters
Chemical Substances	Chlorides ; Receptors, GABA ; Symporters ; gamma-Aminobutyric Acid (56-12-2) ; Potassium (RWP5GA015D)
Language	English
Publishing date	2021-02-02
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	2997-x
ISSN	1083-351X ; 0021-9258
ISSN (online)	1083-351X
ISSN	0021-9258
DOI	10.1016/j.jbc.2021.100364
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uc I Zs.108: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Clinical variables for predicting type-1 and type-2 non-ST segment elevation myocardial infarction in those presenting with ischemic symptoms.

Ha, Edward T / Ng, Brandon / Afshaq, Abeer / Fleischman, Eitan / Hosain, Batool / Sharma, Roohi / Gaeta, Theodore J / Parikh, Manish / Peterson, Stephen J / Aronow, Wilbert S

Archives of medical sciences. Atherosclerotic diseases

2022 Volume 7, Page(s) e42–e48

Abstract: Introduction: The accuracy of detecting myocardial infarction (MI) has greatly improved with the advent of more sensitive assays, and this has led to etiologic subtyping. Distinguishing between type 1 and type 2 non-ST-segment elevation myocardial ... ...

Abstract	Introduction: The accuracy of detecting myocardial infarction (MI) has greatly improved with the advent of more sensitive assays, and this has led to etiologic subtyping. Distinguishing between type 1 and type 2 non-ST-segment elevation myocardial infarction (NSTEMI) early in the clinical course allows for the most appropriate advanced diagnostic procedures and most efficacious treatments. The purpose of this study was to investigate the predictive effect of demographic and clinical variables on predicting NSTEMI subtypes in patients presenting with ischemic symptoms. Material and methods: We performed a single institution retrospective cohort study of patients who presented to the emergency department (ED) with ischemic signs and symptoms consistent with non-ST-segment myocardial infarction, for whom results of coronary angiography were available. We analyzed demographic, laboratory, echocardiography and angiography data to determine predictors of NSTEMI sub-types. Results: Five hundred and forty-six patients were enrolled; 426 patients were found on coronary angiography to have type 1 acute MI (T1AMI), whereas 120 patients had type 2 acute MI (T2AMI). Age (OR per year = 1.03 (1.00, 1.05), Conclusions: Key clinical variables such as age, prior MI, L/H ratio, percentage change in troponin I, and presence of RWMA on echocardiogram may be utilized as significant predictors of T1AMI in patients presenting with ischemic symptoms to the ED.
Language	English
Publishing date	2022-07-08
Publishing country	Poland
Document type	Journal Article
ISSN	2451-0629
ISSN	2451-0629
DOI	10.5114/amsad/149921
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders.

Huffman, Brandon M / Singh, Harshabad / Ali, Lestat R / Horick, Nora / Wang, S Jennifer / Hoffman, Megan T / Metayer, Katherine A / Murray, Shayla / Bird, Alexandra / Abrams, Thomas A / Biller, Leah H / Chan, Jennifer A / Meyerhardt, Jeffrey A / McCleary, Nadine J / Goessling, Wolfram / Patel, Anuj K / Wisch, Jeffrey S / Yurgelun, Matthew B / Mouw, Kent /

Reardon, Brendan / Van Allen, Eliezer M / Zerillo, Jessica A / Clark, Jeffrey W / Parikh, Aparna / Mayer, Robert J / Schlechter, Benjamin / Ng, Kimmie / Kumar, Sunil / Del Vecchio Fitz, Catherine / Kuperwasser, Charlotte / Hanna, Glenn J / Coveler, Andrew L / Rubinson, Douglas A / Welsh, Emma L / Pfaff, Kathleen / Rodig, Scott / Dougan, Stephanie K / Cleary, James M

Journal for immunotherapy of cancer

2024 Volume 12, Issue 1

Abstract: ... T cells on pretreatment biopsy. Patients who benefited from pembrolizumab had decreasing TTMV-HPV DNA ... anal cancers have low numbers of tumor-associated CD8+PD-1+ T cells and are resistant to pembrolizumab. ...

Abstract	Background: Recent trials suggest that programmed cell death 1 (PD-1)-directed immunotherapy may be beneficial for some patients with anal squamous cell carcinoma and biomarkers predictive of response are greatly needed. Methods: This multicenter phase II clinical trial (NCT02919969) enrolled patients with metastatic or locally advanced incurable anal squamous cell carcinoma (n=32). Patients received pembrolizumab 200 mg every 3 weeks. The primary endpoint of the trial was objective response rate (ORR). Exploratory objectives included analysis of potential predictive biomarkers including assessment of tumor-associated immune cell populations with multichannel immunofluorescence and analysis of circulating tumor tissue modified viral-human papillomavirus DNA (TTMV-HPV DNA) using serially collected blood samples. To characterize the clinical features of long-term responders, we combined data from our prospective trial with a retrospective cohort of patients with anal cancer treated with anti-PD-1 immunotherapy (n=18). Results: In the phase II study, the ORR to pembrolizumab monotherapy was 9.4% and the median progression-free survival was 2.2 months. Despite the high level of HPV positivity observed with circulating TTMV-HPV DNA testing, the majority of patients had low levels of tumor-associated CD8+PD-1+ T cells on pretreatment biopsy. Patients who benefited from pembrolizumab had decreasing TTMV-HPV DNA scores and a complete responder's TTMV-HPV DNA became undetectable. Long-term pembrolizumab responses were observed in one patient from the trial (5.3 years) and three patients (2.5, 6, and 8 years) from the retrospective cohort. Long-term responders had HPV-positive tumors, lacked liver metastases, and achieved a radiological complete response. Conclusions: Pembrolizumab has durable efficacy in a rare subset of anal cancers. However, despite persistence of HPV infection, indicated by circulating HPV DNA, most advanced anal cancers have low numbers of tumor-associated CD8+PD-1+ T cells and are resistant to pembrolizumab.
MeSH term(s)	Humans ; Retrospective Studies ; Prospective Studies ; Programmed Cell Death 1 Receptor ; Papillomavirus Infections ; Carcinoma, Squamous Cell/drug therapy ; Anus Neoplasms/drug therapy ; DNA ; Antibodies, Monoclonal, Humanized
Chemical Substances	pembrolizumab (DPT0O3T46P) ; Programmed Cell Death 1 Receptor ; DNA (9007-49-2) ; Antibodies, Monoclonal, Humanized
Language	English
Publishing date	2024-01-25
Publishing country	England
Document type	Multicenter Study ; Clinical Trial, Phase II ; Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	2719863-7
ISSN	2051-1426 ; 2051-1426
ISSN (online)	2051-1426
ISSN	2051-1426
DOI	10.1136/jitc-2023-008436
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer.

Singh, Harshabad / Sahgal, Pranshu / Kapner, Kevin / Corsello, Steven M / Gupta, Hersh / Gujrathi, Rahul / Li, Yvonne Y / Cherniack, Andrew D / El Alam, Raquelle / Kerfoot, Joseph / Andrews, Elizabeth / Lee, Annette / Nambiar, Chetan / Hannigan, Alison M / Remland, Joshua / Brais, Lauren / Leahy, Meghan E / Rubinson, Douglas A / Schlechter, Benjamin L /

Clinical cancer research : an official journal of the American Association for Cancer Research

2024 Volume 30, Issue 8, Page(s) 1669–1684

Abstract: Purpose: ERBB2-amplified colorectal cancer is a distinct molecular subtype with expanding treatments. Implications of concurrent oncogenic RAS/RAF alterations are not known.: Experimental design: Dana-Farber and Foundation Medicine Inc. Colorectal ... ...

Abstract	Purpose: ERBB2-amplified colorectal cancer is a distinct molecular subtype with expanding treatments. Implications of concurrent oncogenic RAS/RAF alterations are not known. Experimental design: Dana-Farber and Foundation Medicine Inc. Colorectal cancer cohorts with genomic profiling were used to identify ERBB2-amplified cases [Dana-Farber, n = 47/2,729 (1.7%); FMI, n = 1857/49,839 (3.7%)]. Outcomes of patients receiving HER2-directed therapies are reported (Dana-Farber, n = 9; Flatiron Health-Foundation Medicine clinicogenomic database, FH-FMI CGDB, n = 38). Multisite HER2 IHC and genomic profiling were performed to understand HER2 intratumoral and interlesional heterogeneity. The impact of concurrent RAS comutations on the effectiveness of HER2-directed therapies were studied in isogenic colorectal cancer cell lines and xenografts. Results: ERBB2 amplifications are enriched in left-sided colorectal cancer. Twenty percent of ERBB2-amplified colorectal cancers have co-occurring oncogenic RAS/RAF alterations. While RAS/RAF WT colorectal cancers typically have clonal ERBB2 amplification, colorectal cancers with co-occurring RAS/RAF alterations have lower level ERRB2 amplification, higher intratumoral heterogeneity, and interlesional ERBB2 discordance. These distinct genomic patterns lead to differential responsiveness and patterns of resistance to HER2-directed therapy. ERBB2-amplified colorectal cancer with RAS/RAF alterations are resistant to trastuzumab-based combinations, such as trastuzumab/tucatinib, but retain sensitivity to trastuzumab deruxtecan in in vitro and murine models. Trastuzumab deruxtecan shows clinical efficacy in cases with high-level ERBB2-amplified RAS/RAF coaltered colorectal cancer. Conclusions: Co-occurring RAS/RAF alterations define a unique subtype of ERBB2-amplified colorectal cancer that has increased intratumoral heterogeneity, interlesional discordance, and resistance to trastuzumab-based combinations. Further examination of trastuzumab deruxtecan in this previously understudied cohort of ERBB2-amplified colorectal cancer is warranted.
MeSH term(s)	Humans ; Animals ; Mice ; DNA Copy Number Variations ; Gene Amplification ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/metabolism ; Receptor, ErbB-2/metabolism ; Trastuzumab/pharmacology ; Trastuzumab/therapeutic use ; Treatment Outcome ; Mutation
Chemical Substances	Receptor, ErbB-2 (EC 2.7.10.1) ; Trastuzumab (P188ANX8CK) ; ERBB2 protein, human (EC 2.7.10.1)
Language	English
Publishing date	2024-02-12
Publishing country	United States
Document type	Journal Article
ZDB-ID	1225457-5
ISSN	1557-3265 ; 1078-0432
ISSN (online)	1557-3265
ISSN	1078-0432
DOI	10.1158/1078-0432.CCR-23-2581
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4223: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Development of Expert-Level Classification of Seizures and Rhythmic and Periodic Patterns During EEG Interpretation.

Jing, Jin / Ge, Wendong / Hong, Shenda / Fernandes, Marta Bento / Lin, Zhen / Yang, Chaoqi / An, Sungtae / Struck, Aaron F / Herlopian, Aline / Karakis, Ioannis / Halford, Jonathan J / Ng, Marcus C / Johnson, Emily L / Appavu, Brian L / Sarkis, Rani A / Osman, Gamaleldin / Kaplan, Peter W / Dhakar, Monica B / Arcot Jayagopal, Lakshman /

Sheikh, Zubeda / Taraschenko, Olga / Schmitt, Sarah / Haider, Hiba A / Kim, Jennifer A / Swisher, Christa B / Gaspard, Nicolas / Cervenka, Mackenzie C / Rodriguez Ruiz, Andres A / Lee, Jong Woo / Tabaeizadeh, Mohammad / Gilmore, Emily J / Nordstrom, Kristy / Yoo, Ji Yeoun / Holmes, Manisha G / Herman, Susan T / Williams, Jennifer A / Pathmanathan, Jay / Nascimento, Fábio A / Fan, Ziwei / Nasiri, Samaneh / Shafi, Mouhsin M / Cash, Sydney S / Hoch, Daniel B / Cole, Andrew J / Rosenthal, Eric S / Zafar, Sahar F / Sun, Jimeng / Westover, M Brandon

Neurology

2023 Volume 100, Issue 17, Page(s) e1750–e1762

Abstract: Background and objectives: Seizures (SZs) and other SZ-like patterns of brain activity can harm the brain and contribute to in-hospital death, particularly when prolonged. However, experts qualified to interpret EEG data are scarce. Prior attempts to ... ...

Abstract	Background and objectives: Seizures (SZs) and other SZ-like patterns of brain activity can harm the brain and contribute to in-hospital death, particularly when prolonged. However, experts qualified to interpret EEG data are scarce. Prior attempts to automate this task have been limited by small or inadequately labeled samples and have not convincingly demonstrated generalizable expert-level performance. There exists a critical unmet need for an automated method to classify SZs and other SZ-like events with expert-level reliability. This study was conducted to develop and validate a computer algorithm that matches the reliability and accuracy of experts in identifying SZs and SZ-like events, known as "ictal-interictal-injury continuum" (IIIC) patterns on EEG, including SZs, lateralized and generalized periodic discharges (LPD, GPD), and lateralized and generalized rhythmic delta activity (LRDA, GRDA), and in differentiating these patterns from non-IIIC patterns. Methods: We used 6,095 scalp EEGs from 2,711 patients with and without IIIC events to train a deep neural network, Results: SPaRCNet Discussion: SPaRCNet Classification of evidence: This study provides Class II evidence that among patients with epilepsy or critical illness undergoing EEG monitoring,
MeSH term(s)	Humans ; Reproducibility of Results ; Hospital Mortality ; Seizures ; Electroencephalography/methods ; Epilepsy/diagnosis
Language	English
Publishing date	2023-03-06
Publishing country	United States
Document type	Journal Article ; Research Support, U.S. Gov't, Non-P.H.S. ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
ZDB-ID	207147-2
ISSN	1526-632X ; 0028-3878
ISSN (online)	1526-632X
ISSN	0028-3878
DOI	10.1212/WNL.0000000000207127
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui II Zs.153: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MG 18: Show issues
Zs.MO 374: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A prospective study of elderly initiating mirabegron versus antimuscarinics: Patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments.

Bunniran, Suvapun / Davis, Cralen / Kristy, Rita / Ng, Daniel / Schermer, Carol R / Uribe, Claudia / Suehs, Brandon T

Neurourology and urodynamics

2017 Volume 37, Issue 1, Page(s) 177–185

Abstract: ... mirabegron or an antimuscarinic using a validated PRO instrument, OAB-Satisfaction (OAB-S).: Methods ... at any time or on any OAB-S scale. There were significant within-group differences at follow-up compared ... to baseline for OAB-S scales: "impact on daily living," with improvement over the 90-day survey period ...

Abstract	Aims: To understand differences in patient reported outcomes (PRO) between patients initiating mirabegron or an antimuscarinic using a validated PRO instrument, OAB-Satisfaction (OAB-S). Methods: This prospective observational study used real-time prescription claims from Humana to identify Medicare patients initiating mirabegron or an antimuscarinic to participate in a series of three phone surveys over ninety days. Results: A total of 1897 mirabegron and 2444 randomly selected antimuscarinic initiators were identified; 174 mirabegron and 193 antimuscarinic initiators completed all three surveys. Among responders, mirabegron initiators were slightly older (76 vs 75 years, P = 0.032), included more males (32% vs 23%, P = 0.044), more likely to have prior OAB treatment (21% vs 13%, P = 0.048), and had greater medication burden (number of unique medications: 10.0 vs 8.7, P = 0.014). There were no between-group differences at any time or on any OAB-S scale. There were significant within-group differences at follow-up compared to baseline for OAB-S scales: "impact on daily living," with improvement over the 90-day survey period for both mirabegron (P = 0.008) and antimuscarinic (P < 0.001); "interruption of day-to-day life," with improvement for both mirabegron (P < 0.001) and antimuscarinic (P < 0.001); and improvement in "OAB control" for mirabegron (P < 0.001) and antimuscarinic (P < 0.001). Conclusions: Mirabegron initiators tended to be older, had a greater number of unique medications and previously tried prescriptions to treat OAB; nonetheless, mirabegron, and antimuscarinic initiators reported similar trends in improvement in PROs over the first 90 days of treatment. Significant improvement in daily impact of OAB was observed after treatment initiation; however, no significant differences between groups were observed.
MeSH term(s)	Acetanilides/therapeutic use ; Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Muscarinic Antagonists/therapeutic use ; Patient Reported Outcome Measures ; Patient Satisfaction ; Prospective Studies ; Thiazoles/therapeutic use ; Treatment Outcome ; Urinary Bladder, Overactive/drug therapy ; Urological Agents/therapeutic use
Chemical Substances	Acetanilides ; Muscarinic Antagonists ; Thiazoles ; Urological Agents ; mirabegron (MVR3JL3B2V)
Language	English
Publishing date	2017-03-31
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	604904-7
ISSN	1520-6777 ; 0733-2467
ISSN (online)	1520-6777
ISSN	0733-2467
DOI	10.1002/nau.23271
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1828: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Deep active learning for Interictal Ictal Injury Continuum EEG patterns.

Ge, Wendong / Jing, Jin / An, Sungtae / Herlopian, Aline / Ng, Marcus / Struck, Aaron F / Appavu, Brian / Johnson, Emily L / Osman, Gamaleldin / Haider, Hiba A / Karakis, Ioannis / Kim, Jennifer A / Halford, Jonathan J / Dhakar, Monica B / Sarkis, Rani A / Swisher, Christa B / Schmitt, Sarah / Lee, Jong Woo / Tabaeizadeh, Mohammad /

Rodriguez, Andres / Gaspard, Nicolas / Gilmore, Emily / Herman, Susan T / Kaplan, Peter W / Pathmanathan, Jay / Hong, Shenda / Rosenthal, Eric S / Zafar, Sahar / Sun, Jimeng / Brandon Westover, M

Journal of neuroscience methods

2020 Volume 351, Page(s) 108966

Abstract: Objectives: Seizures and seizure-like electroencephalography (EEG) patterns, collectively referred to as "ictal interictal injury continuum" (IIIC) patterns, are commonly encountered in critically ill patients. Automated detection is important for ... ...

Abstract	Objectives: Seizures and seizure-like electroencephalography (EEG) patterns, collectively referred to as "ictal interictal injury continuum" (IIIC) patterns, are commonly encountered in critically ill patients. Automated detection is important for patient care and to enable research. However, training accurate detectors requires a large labeled dataset. Active Learning (AL) may help select informative examples to label, but the optimal AL approach remains unclear. Methods: We assembled >200,000 h of EEG from 1,454 hospitalized patients. From these, we collected 9,808 labeled and 120,000 unlabeled 10-second EEG segments. Labels included 6 IIIC patterns. In each AL iteration, a Dense-Net Convolutional Neural Network (CNN) learned vector representations for EEG segments using available labels, which were used to create a 2D embedding map. Nearest-neighbor label spreading within the embedding map was used to create additional pseudo-labeled data. A second Dense-Net was trained using real- and pseudo-labels. We evaluated several strategies for selecting candidate points for experts to label next. Finally, we compared two methods for class balancing within queries: standard balanced-based querying (SBBQ), and high confidence spread-based balanced querying (HCSBBQ). Results: Our results show: 1) Label spreading increased convergence speed for AL. 2) All query criteria produced similar results to random sampling. 3) HCSBBQ query balancing performed best. Using label spreading and HCSBBQ query balancing, we were able to train models approaching expert-level performance across all pattern categories after obtaining ∼7000 expert labels. Conclusion: Our results provide guidance regarding the use of AL to efficiently label large EEG datasets in critically ill patients.
MeSH term(s)	Cluster Analysis ; Electroencephalography ; Humans ; Neural Networks, Computer ; Seizures/diagnosis
Language	English
Publishing date	2020-10-22
Publishing country	Netherlands
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
ZDB-ID	282721-9
ISSN	1872-678X ; 0165-0270
ISSN (online)	1872-678X
ISSN	0165-0270
DOI	10.1016/j.jneumeth.2020.108966
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1486: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Subcutaneous sodium valproate in palliative care: A systematic review.

Tan, Sheryn / Ng, Jeng Swen / Tang, Charis / Stretton, Brandon / Kovoor, Joshua / Gupta, Aashray / Delloso, Thomson / Zhang, Tony / Goh, Rudy / El-Masri, Shaddy / Kiley, Michelle / Maddocks, Ian / Harroud, Adil / Stacpoole, Sybil / Crawford, Gregory / Bacchi, Stephen

Palliative medicine

2024 Volume 38, Issue 4, Page(s) 492–497

Abstract: Background: Seizures are an important palliative symptom, the management of which can be complicated by patients' capacity to swallow oral medications. In this setting, and the wish to avoid intravenous access, subcutaneous infusions may be employed. ... ...

Abstract	Background: Seizures are an important palliative symptom, the management of which can be complicated by patients' capacity to swallow oral medications. In this setting, and the wish to avoid intravenous access, subcutaneous infusions may be employed. Options for antiseizure medications that can be provided subcutaneously may be limited. Subcutaneous sodium valproate may be an additional management strategy. Aim: To evaluate the published experience of subcutaneous valproate use in palliative care, namely with respect to effectiveness and tolerability. Design: A systematic review was registered (PROSPERO CRD42023453427), conducted and reported according to PRISMA reporting guidelines. Data sources: The databases PubMed, EMBASE and Scopus were searched for publications until August 11, 2023. Results: The searches returned 429 results, of which six fulfilled inclusion criteria. Case series were the most common study design, and most studies included <10 individuals who received subcutaneous sodium valproate. There were three studies that presented results on the utility of subcutaneous sodium valproate for seizure control, which described it to be an effective strategy. One study also described it as an effective treatment for neuropathic pain. The doses were often based on presumed 1:1 oral to subcutaneous conversion ratios. Only one study described a local site adverse reaction, which resolved with a change of administration site. Conclusions: There are limited data on the use of subcutaneous sodium valproate in palliative care. However, palliative symptoms for which subcutaneous sodium valproate have been used successfully are seizures and neuropathic pain. The available data have described few adverse effects, supporting its use with an appropriate degree of caution.
MeSH term(s)	Humans ; Valproic Acid/adverse effects ; Palliative Care ; Seizures/chemically induced ; Seizures/drug therapy ; Neuralgia/drug therapy
Chemical Substances	Valproic Acid (614OI1Z5WI)
Language	English
Publishing date	2024-03-05
Publishing country	England
Document type	Systematic Review ; Journal Article
ZDB-ID	639247-7
ISSN	1477-030X ; 0269-2163
ISSN (online)	1477-030X
ISSN	0269-2163
DOI	10.1177/02692163241234597
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2285: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito